Last reviewed · How we verify
Abrupt cessation of phentermine pharmacotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Abrupt cessation of phentermine pharmacotherapy (Abrupt cessation of phentermine pharmacotherapy) — Center for Weight Management, California.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Abrupt cessation of phentermine pharmacotherapy TARGET | Abrupt cessation of phentermine pharmacotherapy | Center for Weight Management, California | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Abrupt cessation of phentermine pharmacotherapy CI watch — RSS
- Abrupt cessation of phentermine pharmacotherapy CI watch — Atom
- Abrupt cessation of phentermine pharmacotherapy CI watch — JSON
- Abrupt cessation of phentermine pharmacotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Abrupt cessation of phentermine pharmacotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/abrupt-cessation-of-phentermine-pharmacotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab